anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Disclosed is a method for lyophilising particles (30) comprising frozen liquid having a pharmaceutical compound contained therein. A heat conducting container (15, 15') having a bottom and side walls is filled with a bed (29) of the particles, the bed comprising multiple layers of the particles and having an aspect ratio (ratio of the width of the bed to its height) of not less than 1. A heat source (5a-c) is located above a top layer of the particles, the heat source having a surface directed to a top layer of the bed, the surface having an emissivity coefficient of at least 0.4. The particles filled in the container are subjected to a reduced pressure. At least the bottom of the container and the surface are heated to provide heat to the particles to support sublimation of the frozen liquid at the reduced pressure, and after the frozen liquid is sublimated, stopping the provision of heat to the particles. The invention also includes to a pharmaceutical pack comprising a container having contained therein at least one particle obtained via this method.
These patients underwent root canal treatment due to pain in their molar teeth. The file system used in this arm was WaveOne(Dentsply), a reciprocating file system that moves in 150° anticlockwise and 30° clockwise motion and prepares a root canal.
Wild species of crops serve as a valuable germplasm resource for breeding of modern cultivars. Rice (Oryza sativa L.) is a vital global staple food. However, research on genome evolution and diversity of wild rice species remains limited. Here, we present nearly complete genomes of 13 representative wild rice species. By integrating with four previously published genomes for pangenome analysis, a total of 101,723 gene families are identified across the genus, including 9834 (9.67%) core gene families. Additionally, 63,881 gene families absent in cultivated rice species but present in wild rice species are discovered. Extensive structural rearrangements, sub-genomes exchanges, widespread allelic variations, and regulatory sequence variations are observed in wild rice species. Interestingly, expanded but less diverse disease resistance genes in the genomes of cultivated rice, likely due to the loss of some resistance genes and the fixing and amplification of genes encoding resistance genes to specific diseases during domestication and artificial selection. This study not only reveals natural variations valuable for gene-level studies and breeding selection but also enhances our understanding on rice evolution and domestication.
OBJECTIVES: Presently, the management of direct oral anticoagulants lacks specific guidelines for patients before and after transplant, particularly for lung transplant recipients. We aimed to consolidate the existing literature on direct oral anticoagulants and explore their implications in lung transplant recipients.
MATERIALS AND METHODS: We conducted a comprehensive search in PubMed and Google Scholar databases for studies published between January 2000 and December 2022, using specific search terms. We only included studies involving lung transplant recipients and focusing on direct oral anticoagulants.
RESULTS: Five relevant publications were identified, providing varied insights. None of the studies specifically addressed bleeding complications associated with direct oral anticoagulants in lung transplant recipients. Limited details were available on the type of solid-organ transplant or the specific direct oral anticoagulant used in these studies.
CONCLUSIONS: Varied bleeding complications associated with direct oral anticoagulants in lung transplant recipients were reported, but studies lacked specificity on transplant type and direct oral anticoagulant variations. Notably, the incidence of venous thrombotic embolism in lung transplant recipients was comparatively higher than in other solid-organ transplant recipients, potentially linked to factors such as corticosteroid therapy, calcineurin inhibitors, and cytomegalovirus infections. Our synthesis on findings of use of direct oral anticoagulant in lung transplant recipients emphasized challenges of managing these medications in urgent transplant situations. Recommendations from experts suggested caution in initiation of direct oral anticoagulants posttransplant until stability in renal and hepatic function is achieved. The limited evidence on safety of direct oral anticoagulants in lung transplant recipients underscores the need for further research and guidance in this specific patient population.
Neck pain is one of the most common problems affecting the health of Americans and is a leading reason for using complementary or alternative medical (CAM) therapies. Therapeutic massage is one of the most popular CAM treatments for neck pain, but little is known about its effectiveness. This study will lay the groundwork for a full-scale trial that evaluates the effectiveness of therapeutic massage for chronic neck pain.

The study will involve two phases. During Phase I, researchers will develop and pre-test key components for a randomized clinical trial. In Phase II, the safety and efficacy of massage for CNP will be evaluated. The changes in symptoms, function, and quality of life in massage and self care groups will be evaluated midway through treatment, at the end of treatment and at 6 months post randomization.
The invention discloses a CDCM culture medium and application thereof, wherein the CDCM culture medium comprises alpha-MEM culture medium, insulin, selenium element, L-ascorbic acid, b-FGF, EGF, TGF-beta, hydrocortisone, IGF, heparin and NaHCO  3  And a transporter. The invention also discloses a culture method of the umbilical cord blood mesenchymal stem cells. The invention uses a chemically defined medium to culture cells. The culture medium with the determined chemical components can stably maintain the growth of stem cells, and realize the mass expansion of umbilical cord blood mesenchymal stem cells. The invention optimizes the protein matrix material coated on the culture dish, and effectively supports the growth of umbilical cord blood mesenchymal stem cells in CDCM. The invention has the most remarkable advantages of solving the problems of various hidden dangers caused by conventional culture with the fetal bovine serum with a certain concentration or limited large-scale amplification caused by autologous plasma, and the like, and has great significance to the field of cell therapy.
See DOSAGE AND ADMINISTRATION, COMPATIBILITY for diluents compatible with Vecuronium Bromide for Injection. 

Single-Dose Use: When reconstituted with compatible IV solutions not containing an antimicrobial preservative (e.g., sterile water for injection), refrigerate and use within 24 hours. Discard unused portion. 

Multi-Dose Use: (NOT FOR USE IN NEWBORNS.) When reconstituted with bacteriostatic water for injection, use within 5 days. The reconstituted solution may be stored at room temperature or refrigerated. 

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. 

Risk of Medication Errors: Accidental administration of neuromuscular blocking agents may be fatal. Store Vecuronium Bromide for Injection with the cap and ferrule intact and in a manner that minimizes the possibility of selecting the wrong product.
Erythropoietin has lately been shown to exert others than merely hematopoietic functions. Due to attenuation of cell apoptosis and necrosis and/or enhancing neovascularisation, erythropoietin could be protective after myocardial ischemia and reperfusion and lead to infarct size reduction and improvement in left ventricular function. In a controlled clinical trial, short-term administration of erythropoietin in patients with ischemic stroke was associated with a significantly better functional recovery, with a lower level of circulating damage markers and a strong trend to smaller infarct sizes measured by magnetic resonance imaging. While leaving hematocrit and platelet counts unchanged, short-term administration of erythropoietin was shown to be safe and very well tolerated (no side effects reported or observed). The protective effects of short-term erythropoietin in acute ischemic brain damage are further evaluated in an ongoing multi-center trial in Germany. Considering the preclinical and clinical data erythropoietin is an attractive candidate to be evaluated in patients with acute myocardial infarction. In a pilot trial enrolling 22 patients with acute myocardial infarction short-term administration of erythropoietin was shown to be safe and to significantly increase the level of endothelial progenitor cells after percutaneous coronary intervention. However, the very small population did not allow evaluating the benefit in left ventricular function or clinical outcomes.

The aim of the REVIVAL-3 study is to investigate whether there is additional benefit of short-term administration of erythropoietin in patients with acute myocardial infarction after successful primary percutaneous coronary intervention (PCI) in terms of left ventricular ejection fraction.
In Phase I, patients with NSCLC harboring the EGFRT790M mutation and prior failure with EGFR-TKIs were enrolled. Using a "3+3" design, dose escalation and expansion studies were conducted to evaluate the safety and pharmacokinetics of FHND-9041 at doses of 40, 80, 120, and 180 mg/day, with 3 to 9 patients per group. Phase II utilized the RP2D of 80 mg QD, determined from Phase I, to assess the efficacy and safety of FHND-9041 in patients with locally advanced or metastatic NSCLC. The primary endpoint was Objective Response Rate (ORR), with Progression-Free Survival (PFS) as a secondary endpoint. Tumor response and disease progression were evaluated according to RECIST 1.1 criteria, and safety was assessed per CTCAE-5.0 standards.
BACKGROUND: Cardiogenic shock (CS) is a significant complication of Takotsubo syndrome (TTS), contributing to heightened mortality and morbidity. Despite this, the Society for Cardiovascular Angiography and Interventions (SCAI) staging system for CS severity lacks validation in patients with TTS and CS. This study aimed to characterize a patient cohort with TTS using the SCAI staging system and assess its utility in cases of TTS complicated by CS.
METHODS AND RESULTS: From a TTS national registry, 1591 consecutive patients were initially enrolled and stratified into 5 SCAI stages (A through E). Primary outcome was all-cause in-hospital mortality; secondary end points were TTS-related in-hospital complications and 1-year all-cause mortality. After exclusions, the final cohort comprised 1163 patients, mean age 71.0±11.8 years, and 87% were female. Patients were categorized across SCAI shock stages as follows: A 72.1%, B 12.2%, C 11.2%, D 2.7%, and E 1.8%. Significant variations in baseline demographics, comorbidities, clinical presentations, and in-hospital courses were observed across SCAI shock stages. After multivariable adjustment, each higher SCAI shock stage showed a significant association with increased in-hospital mortality (adjusted odds ratio: 1.77-29.31) compared with SCAI shock stage A. Higher SCAI shock stages were also associated with increased 1-year mortality.
CONCLUSIONS: In a large multicenter patient cohort with TTS, the functional SCAI shock stage classification effectively stratified mortality risk, revealing a continuum of escalating shock severity with higher stages correlating with increased in-hospital mortality. This study highlights the applicability and prognostic value of the SCAI staging system in TTS-related CS.
FIELD: special-destination fluids. SUBSTANCE: invention relates to viscous aqueous fluid possessing elastic properties and used as thickener in water-based hydraulic fluids, for example in hydraulic breaking fluids in oil-production wells. Surfactants contained in viscoelastic fluid are of zwitterion/amphoteric nature such as dihydroxyalkyl glycinates, alkyl amphoacetate or propionate, alkyl betaine, alkylamidopropyl betaine, and alkylamino mono- or dipropionates obtained from waxes, fats, and oils. Thickening agent is used in combination with water-soluble inorganic salt or organic additive such as phthalic acid, salicylic acid, or their salts. Zwitterionic surfactant represents 77% and more of the weight of all surfactants and 0.5 to 10% of the total weight of fluid. EFFECT: improved viscosity characteristics in dependence of shear thrust. 99 cl, 5 dwg, 5 tbl, 10 ex
PURPOSE: To provide a medical information management device which can input medical information in accordance with the consideration of a doctor and which is flexible and handleable. CONSTITUTION: Medical information inputted by a keyboard 9 is received by an input interface 13. When the head of a word on information is an alphabet, it is identified to be the name of a medicine and the dosage and to be the usage of the medicine when it is a number by an identification device 15. When identified information is the usage of the medicine, a classification device 17 gives order information showing a classification order to the memory of information, and a prescription group and the content are classified in terms of an hierarchy. Information is made into data for display by a data processor 19, is displayed on a display device 7 and it is simultaneously stored in a storage device 21.  When the indication of shift, elimination, addition and copy is given by a mouse 11 and the like, the classification device 17 automatically rewrites order information, re-classifies it and information is displayed on the display device 7. The information are transmitted to a host computer through a communication interface 23.
Sleep is essential for overall health, and its disruption is linked to increased risks of metabolic, cognitive, and cardiovascular dysfunctions; however, the molecular mechanisms remain poorly understood. This study investigated how sleep disturbances contribute to metabolic imbalance and cognition impairment using a chronic sleep fragmentation (SF) mouse model. SF mice exhibited impaired cognition, glucose metabolism, and insulin sensitivity compared with controls. We identified increased acetate levels in hypothalamic astrocytes as a defensive response in SF mice. Through acetate infusion or astrocyte-specific Acss1 deletion to elevate acetate levels, we observed mitigated metabolic and cognitive impairments in SF mice. Mechanistically, acetate binds and activates pyruvate carboxylase, thereby restoring glycolysis and the tricarboxylic acid cycle. Among individuals most commonly affected by SF, patients with obstructive sleep apnea exhibited elevated acetate levels when coupled with type 2 diabetes. Our study uncovers the protective effect of acetate against sleep-induced metabolic and cognitive impairments.
The urodynamic study included free uroflowmetry, postvoid residual, filling and voiding cystometry, and a urethral pressure profile. The filling cystometry and urethral pressure profile were performed with 37 degrees C normal saline similar to body temperature at an infusion rate of 80 ml/min. All patients received a pre- and a post-operative urodynamic evaluation, in which pre-operative evaluation was conducted 1-4 weeks before TOT procedure, and post-operative evaluation was done at 4-6 weeks follow-up.

Complete multichannel urodynamic studies including free uroflowmetry, filling and voiding cystometry, and urethral pressure profile was performed in each patient. The urodynamic parameters measured were the maximum flow rate (Qmax), voided volume, post-void residual volume (PVR), and detrusor pressure at Qmax (Pdet. Qmax). The filling cystometry and urethral pressure profile were performed with 37 degrees C normal saline at an infusion rate of 80 ml/min. All data were recorded and analyzed using a Medical Measurement Systems (MMS UD-200, Enschede, The Netherlands). All data in this study will be expressed as mean ± SEM. After checking the normality and variance of data, two-way ANOVAs were used to assess the difference in values among testing groups and time points; and post hoc Student-Newman-Keuls tests were used to compare the means of groups when there was a significant difference between groups. Significance was set at p\<0.05.
Patients aged 16 or over with (1) RP, diagnosed by a clinician, meeting the European Society of Cardiology (ESC) diagnostic criteria, and (2) where the aetiology of the RP is defined as idiopathic (i.e. there is no other aetiology identified, such as infective, malignant, post cardiac injury, as part of an autoimmune condition, as part of another known auto-inflammatory disease).
Patients will receive an ultrasound-guided injection consisting of 3 ml hyaluronic acid (Durolane™) mixed with 40 mg triamcinolone (Kenalog™) into their hip joint. Patients will also receive an 8-week physiotherapy protocol, consisting of 8 visits. The protocol will consist of 1 visit per week.
FIELD: medicine. ^ SUBSTANCE: group of inventions concerns medicine, namely to the agents strengthening effect of processing by focused ultrasound of high intensity (HIFU). The agent, strengthening effect of HIFU processing, intended for HIFU-therapy, represents a substance which can reduce level of HIFU energy in a target site (EEF), containing the discrete phase consisting of a kernel, concluded in a capsule from a membrane-forming substance; and the continuous phase consisting of water medium, thus the discrete phase is homogeneously distributed in the continuous phase. The way of processing of a target site using the HIFU method consists in intravenous introduction of an effective dose of the specified strengthening agent by means of continuous and fast intravenous installation or bolus injection to the patient 0-168 hours prior to HIFU-therapy application. The way of an agent screening strengthening effect of HIFU processing, consists in HIFU-therapy application - to a concrete tissue, calculation of EEF(initial) energy, introduction of a strengthening agent-candidate in a biological tissue, measurement of EEF(experim.) energy, comparison of EEF(initial) and EEF(experim.), and in a choice of the strengthening agent-candidate concerning EEF(initial) to EEF(initial) it is more than 1. The given group of inventions allows reducing quantity of the acoustic energy necessary for damage of a target tissue, in unit of volume of a tissue in the course of HIFU processing, to reduce time of processing of target area and to improve therapeutic effects. ^ EFFECT: reduction of quantity of the acoustic energy necessary for damage of a target tissue, in unit of volume of a tissue in the course of HIFU processing, reduction of time of processing of target area and improvement of therapeutic effects. ^ 19 cl, 24 ex, 10 tbl
Metronidazole is present in human milk at concentrations similar to maternal serum levels, and infant serum levels can be close to or comparable to infant therapeutic levels. There are no data on the effects of metronidazole on milk production. Animal studies have shown the potential for tumorigenicity after oral metronidazole was administered chronically to rats and mice (see PRECAUTIONS, Carcinogenesis, Mutagenesis, Impairment of Fertility). This drug is not intended to be administered chronically; therefore, the clinical relevance of the findings of the animal studies is unclear. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Metronidazole tablets and any potential adverse effects on the breastfed infant from Metronidazole tablets or from the underlying maternal condition. Alternatively, a nursing mother may choose to pump and discard human milk for the duration of metronidazole therapy, and for 48 hours after the last dose and feed her infant stored human milk or formula.
A SLAP (Superior Labrum Anterior to Posterior) lesion is a specific type of shoulder injury that involves damage to the superior labrum, which is the cartilage rim around the socket of the shoulder joint. This type of injury typically occurs at the long head of the biceps tendon attaches to the labrum. The patient may feel pain, popping sensations and decreased range of motion in the shoulder.1 SLAP lesions are occurring in younger individuals,who playing sports that require repetitive overhead motions and presenting in individuals who have shoulder trauma injury,such as a fall or a direct blow to the shoulder.5There are four main types of SLAP lesions: in this research including Type IV: That is characterized by a bucket-handle tear of the superior labrum that extends into the biceps tendon. The torn portion of the labrum is displaced into the joint and the biceps tendon may be partially or completely detached.The prevalence of SLAP lesions as a cause of shoulder pain is estimated to be around 6-26% in the general population. However, the prevalence can vary depending on the specific population being studied, such as athletes or individuals with specific occupations that involve repetitive overhead activities.Treatment of SLAP type IV is Biceps tenodesis which was recently described, used suture anchor for fixation the biceps tendon to proximal humerus to obtain the stability of glenohumeral muscle. Fixation methods include tenodesis through a bone tunnel, the keyhole method, soft tissue tenodesis to the rotator interval or conjoint tendon, interference screw fixation, and suture anchors tenodesis which have a role in pain relief and maintain biceps muscle strength and have a role in preventing cramping. Recently treatment of SLAP lesion is repairing the labrum using suture anchors with Biceps tenodesis.This study prepared to compare the results of Biceps Tenodesis Alone Versus Biceps Tenodesis and labrum Repair in Superior Labrum Anteroposterior (SLAP) Lesion Type IV ?
Individuals will rest for 20 minutes before practicing a novel motor task. Attention will be controlled during this time.
AFNOR 3.6" alerts and "Guidelines" alerts. By alertes Guidelines we mean the clinical recommendations of the Spinal Cord medicine association, i.e. weight relief every 15 to 30 minutes (Bergstrom et al., 1992; Nixon, 1985; Ho and Bogie, 2007) over a period of 1 minute 51 (Coggrave and Rose 2003) for spinal cord injuries. For patients who do not push up, a tilt of at least 25° of seat and 120° of backrest or a minimum of 45° in one block (Dicianno et al. 2009).
These subjects will follow a similar pattern except they will not receive Fitbit Charge HR devices until the second phase of the study (specifically after completion of the 12 week weight loss program). In the first phase, these subjects will receive weekly phone calls to offer them the same attention as the experimental group, but instead of reviewing Fitbit data, these subjects will subjectively report their physical activity in minutes and by qualifying their physical activity as light, moderate, or vigorous. These individuals, after 12 weeks, will return for reassessment. At that time, these individuals will receive Fitbits and receive weekly telephone calls for an additional 12 weeks before returning for a final study visit.